Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic ...
In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...
The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...
A cutting-edge medical experiment in a small trial has demonstrated the effectiveness of a one-time CRISPR gene editing treatment in lowering cholesterol levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback